UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 242

of 'Chemotherapy hepatotoxicity and dose modification in patients with liver disease'

242
TI
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.
AU
Motzer RJ, Johnson T, Choueiri TK, Deen KC, Xue Z, Pandite LN, Carpenter C, Xu CF
SO
Ann Oncol. 2013 Nov;24(11):2927-8. Epub 2013 Oct 9.
 
AD
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA.
PMID